Eléments de l'association

	Basil S. Lewis	4
	Purinergic P2Y Receptor Antagonists (therapeutic use)	1
	Basil S. Lewis *Sauf* Purinergic P2Y Receptor Antagonists (therapeutic use)"	3
	Purinergic P2Y Receptor Antagonists (therapeutic use) *Sauf* Basil S. Lewis"	0
	Basil S. Lewis Et Purinergic P2Y Receptor Antagonists (therapeutic use)	1
	Basil S. Lewis Ou Purinergic P2Y Receptor Antagonists (therapeutic use)	4
	*Corpus*	6045

List of bibliographic references

Number of relevant bibliographic references: 1.

Ident.	Authors (with country if any)	Title
001454	Anna Kotsia [États-Unis] ; Emmanouil S. Brilakis [États-Unis] ; Claes Held [Suède] ; Christopher Cannon [États-Unis] ; Gabriel P. Steg [Royaume-Uni] ; Bernhard Meier [Suisse] ; Frank Cools [Belgique] ; Marc J. Claeys [Belgique] ; Jan H. Cornel [Pays-Bas] ; Philip Aylward [Australie] ; Basil S. Lewis [Israël] ; Douglas Weaver [États-Unis] ; Gunnar Brandrup-Wognsen [Suède] ; Susanna R. Stevens [États-Unis] ; Anders Himmelmann [Suède] ; Lars Wallentin [Suède] ; Stefan K. James [Suède]	Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial.

Wicri

This area was generated with Dilib version V0.6.33.
Data generation: Tue Dec 5 10:43:12 2017. Site generation: Tue Mar 5 14:07:20 2024